283 related articles for article (PubMed ID: 8994122)
21. Cerebrospinal fluid anti-myelin antibodies are related to magnetic resonance measures of disease activity in multiple sclerosis.
Vogt MH; Teunissen CE; Iacobaeus E; Heijnen DA; Breij EC; Olsson T; Brundin L; Killestein J; Dijkstra CD
J Neurol Neurosurg Psychiatry; 2009 Oct; 80(10):1110-5. PubMed ID: 18931010
[TBL] [Abstract][Full Text] [Related]
22. Proton MRS of gadolinium-enhancing MS plaques and metabolic changes in normal-appearing white matter.
Roser W; Hagberg G; Mader I; Brunnschweiler H; Radue EW; Seelig J; Kappos L
Magn Reson Med; 1995 Jun; 33(6):811-7. PubMed ID: 7651118
[TBL] [Abstract][Full Text] [Related]
23. Discrimination of white matter lesions and multiple sclerosis plaques by short echo quantitative 1H-magnetic resonance spectroscopy.
Kapeller P; Ropele S; Enzinger C; Lahousen T; Strasser-Fuchs S; Schmidt R; Fazekas F
J Neurol; 2005 Oct; 252(10):1229-34. PubMed ID: 15895306
[TBL] [Abstract][Full Text] [Related]
24. [Differences in the spectroscopy of the lesions of the remitting relapsing form of multiple sclerosis shown by magnetic resonance].
Martínez-Bisbal MC; Celda B; Martí-Bonmat L; Casanova-Estruch B; Coret-Ferrer F
Rev Neurol; 2002 May 1-15; 34(9):807-12. PubMed ID: 12134339
[TBL] [Abstract][Full Text] [Related]
25. High resolution proton nuclear magnetic resonance studies of human cerebrospinal fluid.
Bell JD; Brown JC; Sadler PJ; Macleod AF; Sönksen PH; Hughes RD; Williams R
Clin Sci (Lond); 1987 May; 72(5):563-70. PubMed ID: 3034477
[TBL] [Abstract][Full Text] [Related]
26. Cerebrospinal fluid cells in multiple sclerosis and other neurological diseases: an immunocytochemical study.
Polman CH; de Groot CJ; Koetsier JC; Sminia T; Veerman AJ
J Neurol; 1987 Jan; 234(1):19-22. PubMed ID: 2950211
[TBL] [Abstract][Full Text] [Related]
27. T and B lymphocytes in the cerebrospinal fluid of various neurological diseases.
Traugott U
J Neurol; 1978 Dec; 219(3):185-97. PubMed ID: 84862
[TBL] [Abstract][Full Text] [Related]
28. Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis.
Tsukada N; Miyagi K; Matsuda M; Yanagisawa N; Yone K
J Neurol Sci; 1991 Aug; 104(2):230-4. PubMed ID: 1940977
[TBL] [Abstract][Full Text] [Related]
29. IL-15 is elevated in serum and cerebrospinal fluid of patients with multiple sclerosis.
Rentzos M; Cambouri C; Rombos A; Nikolaou C; Anagnostouli M; Tsoutsou A; Dimitrakopoulos A; Triantafyllou N; Vassilopoulos D
J Neurol Sci; 2006 Feb; 241(1-2):25-9. PubMed ID: 16316662
[TBL] [Abstract][Full Text] [Related]
30. Localised 1H-MR spectroscopy for metabolic characterisation of diffuse and focal brain lesions in patients infected with HIV.
Simone IL; Federico F; Tortorella C; Andreula CF; Zimatore GB; Giannini P; Angarano G; Lucivero V; Picciola P; Carrara D; Bellacosa A; Livrea P
J Neurol Neurosurg Psychiatry; 1998 Apr; 64(4):516-23. PubMed ID: 9576546
[TBL] [Abstract][Full Text] [Related]
31. The soluble 60-kDa tumour necrosis factor receptor: no difference found between patients with relapsing-remitting multiple sclerosis and controls: increasing levels are associated with the recovery from Guillain-Barré syndrome.
Patzold T; Sindern E; Ossege-Pohle L; Malin JP
J Neurol; 1998 Dec; 245(12):803-8. PubMed ID: 9840353
[TBL] [Abstract][Full Text] [Related]
32. Proton MR spectroscopy in multiple sclerosis: value in establishing diagnosis, monitoring progression, and evaluating therapy.
Richards TL
AJR Am J Roentgenol; 1991 Nov; 157(5):1073-8. PubMed ID: 1927795
[TBL] [Abstract][Full Text] [Related]
33. CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system.
Kastenbauer S; Koedel U; Wick M; Kieseier BC; Hartung HP; Pfister HW
J Neuroimmunol; 2003 Apr; 137(1-2):210-7. PubMed ID: 12667665
[TBL] [Abstract][Full Text] [Related]
34. Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA class I molecules.
Fainardi E; Granieri E; Tola MR; Melchiorri L; Vaghi L; Rizzo R; Castellazzi M; Ceruti S; Paolino E; Baricordi OR
J Neuroimmunol; 2002 Dec; 133(1-2):151-9. PubMed ID: 12446018
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients.
Trentini A; Castellazzi M; Romani A; Squerzanti M; Baldi E; Caniatti ML; Pugliatti M; Granieri E; Fainardi E; Bellini T; Cervellati C
J Neurol Sci; 2017 Jun; 377():133-136. PubMed ID: 28477683
[TBL] [Abstract][Full Text] [Related]
36. Use of serial proton magnetic resonance spectroscopy to differentiate low grade glioma from tumefactive plaque in a patient with multiple sclerosis.
Butteriss DJ; Ismail A; Ellison DW; Birchall D
Br J Radiol; 2003 Sep; 76(909):662-5. PubMed ID: 14500284
[TBL] [Abstract][Full Text] [Related]
37. MR spectroscopy in multiple sclerosis.
De Stefano N; Filippi M
J Neuroimaging; 2007 Apr; 17 Suppl 1():31S-35S. PubMed ID: 17425732
[TBL] [Abstract][Full Text] [Related]
38. Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course.
Sbardella E; Greco A; Stromillo ML; Prosperini L; Puopolo M; Cefaro LA; Pantano P; De Stefano N; Minghetti L; Pozzilli C
Mult Scler; 2013 Apr; 19(4):411-7. PubMed ID: 22917691
[TBL] [Abstract][Full Text] [Related]
39. Proteinase inhibitors in cerebrospinal fluid in multiple sclerosis.
Price P; Cuzner ML
J Neurol Sci; 1979 Jul; 42(2):251-9. PubMed ID: 90128
[TBL] [Abstract][Full Text] [Related]
40. Cerebral metabolism in experimental hydrocephalus: an in vivo 1H and 31P magnetic resonance spectroscopy study.
Braun KP; van Eijsden P; Vandertop WP; de Graaf RA; Gooskens RH; Tulleken KA; Nicolay K
J Neurosurg; 1999 Oct; 91(4):660-8. PubMed ID: 10507389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
